Arovella Therapeutics Limited (ASX:ALA)
0.0860
-0.0040 (-4.44%)
Jan 30, 2026, 2:33 PM AEST
Arovella Therapeutics Revenue
In the fiscal year ending June 30, 2025, Arovella Therapeutics had annual revenue of 3.44M AUD with 76.22% growth. Arovella Therapeutics had revenue of 830.00 in the half year ending June 30, 2025, a decrease of -96.85%.
Revenue
3.44M
Revenue Growth
+76.22%
P/S Ratio
31.43
Revenue / Employee
127.41K
Employees
27
Market Cap
108.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.44M | 1.49M | 76.22% |
| Jun 30, 2024 | 1.95M | 497.46K | 34.20% |
| Jun 30, 2023 | 1.45M | 1.16M | 391.76% |
| Jun 30, 2022 | 295.81K | -693.91K | -70.11% |
| Jun 30, 2021 | 989.72K | -261.71K | -20.91% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 66.87M |
| Radiopharm Theranostics | 12.51M |
| Starpharma Holdings | 5.85M |
| Alterity Therapeutics | 5.44M |
| Imugene | 4.40M |
| Prescient Therapeutics | 4.36M |
| Proteomics International Laboratories | 3.31M |
| Cynata Therapeutics | 1.89M |